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Protection of Nonimmune Volunteers against Rubella by Intravenous
Administration of Normal Human Gamma Globulin
R. Martin du Pan, B. Koechli, and A. Donath From the Faculty of Medicine, University of Geneva,
Geneva, Switzerland
Standard gamma globulin, treated with pepsin and injected intravenously five days
after infection, conferred passive protection against rubella on five volunteers.
Intravenous injection of gamma globulin is superior to intramuscular injection,
because the antibodies enter the bloodstream immediately, and an amount of
antibody sufficient for protection can be given. Injection of standard gamma
globulin is recommended when gamma globulin hyperimmune to rubella virus
is unavailable.
Since the first description of rubella embryopathy
by Gregg in 1942 [1], it has been proved beyond
doubt that rubella infection during the first 16
weeks of pregnancy is a real danger for the em-
bryo [2, 3].
Until every susceptible woman of child-bearing
age can be protected against rubella by an effec-
tive and safe vaccine, passive protection of preg-
nant women who have come into contact with the
disease will continue to be desirable.
The use of either standard or hyperimmune
gamma globulin has been widely proposed since
1946, when Aycock and Ingalls [4] gave gamma
globulin from normal human serum to four chil-
dren infected with or exposed to rubella; however,
reports of the efficacy of intramuscular injection
of gamma globulin have been contradictory [5, 6].
After it became possible to administer attenuated
rubella virus intranasally to produce a benign dis-
ease, Schiff [7] showed that 20 ml of highly titered
immune globulin (titer of neutralizing antibody,
4,096/0.1 rnl) administered 24 hr after intranasal
infection with attenuated rubella virus protected
five nonimmune volunteers. In contrast, 20 ml of
normal gamma globulin administered in the same
way failed to protect four out of six nonimmune
young men.
Received for publication January 17, 1972, and in re-
vised form June 8, 1972.
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The poor results obtained by Schiff with im ad-
ministration of normal gamma globulin could be
explained by an experiment we did with gamma
globulin labeled with 13 11 [8, 9]. Three children
(two to three years of age) and three adults were
injected deeply in the gluteus muscle with 3-5 rnl
of gamma globulin labeled with 1311. The injected
gamma globulin remained at the site of injection
for a rather long time, and only 5%-20% of the
injected gamma globulin was found in the serum
two to five days later. On the other hand, 40%
of the gamma globulin labeled with 13 11 and in-
jected iv remained in the serum of one subject for
a week.
We have already demonstrated that antibodies
to rubella virus, administered iv as human plasma,
persist with measurable titers for up to three weeks
[10], as might be expected from established data
on the half-life of homologous gamma globulin in
man [11].
The risk of inducing serum hepatitis by injec-
tion of human plasma [12] led us to use iv injec-
tion of gamma globulin in our studies.
The preparation of hyperimmune gamma glo-
bulin for protection against rubella is very diffi-
cult, since it is not possible to boost levels of anti-
body by injection of live vaccine into persons
already immune. Furthermore, it is not easy to
find large numbers of persons who are convales-
cing from rubella and willing to give blood. There-
fore, we decided to use standard gamma globulin,
processed to be suitable for iv injection, to obtain
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a sufficiently high level of antibodies in the blood
of the recipients to protect them against rubella.
Experiments
Gamma globulin. Intravenous gamma globu-
lin has already been used on a large scale in Swit-
zerland for treatment of patients with agammaglo-
bulinemia or with serious bacterial infections [13,
14]. It is prepared by pepsin digestion of gamma
globulin dissolved in a solution of glycine
(pH 4.0) for 3 hr at 37 C, followed by neutral-
ization to pH 7.3 [14, 15]. This method removes
most of the anticomplementary properties of stan-
dard gamma globulin. The therapeutic effect in
children suffering from agammaglobulinemia and
in patients with bacterial infections and infections
of the eyes with herpesvirus was generally good.
Gamma globulin can be administered iv in large
quantities without causing pain or serious reac-
tions, and it is rapidly effective [13, 14].
The titers of HAl antibodies to rubella virus
in five lots of normal gamma globulin prepared
and furnished by the Blood Transfusion Labo-
ratory of the Swiss Red Cross at Bern were 1 024
. '
In four lots and 2,048 in one lot.
. To study the protection against rubella con-
ferred by iv gamma globulin, we determined the
following: (l) the half-life of gamma globulin
given iv, (2) the titer of HAl antibodies to ru-
bella virus in the sera of nonimmune recipients
of iv gamma globulin, (3) protection of non-
immune adults by iv injection of standard gamma
globulin.
Half-life of gamma globulin injected iv, Two
healthy, young adult volunteers were injected iv
with 30!1Ci of 131I-labeled gamma globulin after
their thyroid glands were blocked with a 2%
solution of KI. Blood samples were drawn at
different time intervals during one week. After
the presence of free 131I was ruled out, the bio-
logical half-life was determined; it was 7.1 days
in the first person and 8.5 days in the second.
These results are normal according to the litera-
ture [13].
Titer of rubella HAl antibodies in sera. Three
nonimmune adults, two females (CB and FB)
and one male, (JB) received iv infusions of
60, 40, and 60 mI, respectively, of normal
gamma globulin diluted in 200 mI of 0.9% NaCl.
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Table 1. Titer of HAl antibodies to rubella virus
in sera of recipients of I ml of standard gamma
globulin given iv.
Recipient
Gamma globulin and blood CB JB FB
Amount of gamma
globulin injected 60ml 60ml 40 ml
Titer of HAl antibodies/
ml of gamma globulin 1:2,048 I: 1,024 1: 1,024
HAl antibodies in blood
Before injection 0 0 0
After 5 min 1:64 1:32 1:8
After 1 day 1:16 1: 16 1:8
After 5 days 1: 16 1:8 1:8
After 14 days 1:8 <1:8 <1:8
Samples of blood were taken at intervals from
5 min to two weeks.
As can be seen from table 1, iv injection of
40 or 60 ml of standard gamma globulin increased
the level of antibodies in the sera of the recipi-
ents sufficiently to protect them against rubella.
(It is generally accepted that an HAl antibody
titer of 1:8 is protective.)
Protection of nonimmune adults by iv gamma
globulin. To determine whether 30-60 ml of
standard gamma globulin (titer of rubella HAl
antibodies, 1: 1,000) given iv would protect
against rubella, we chose seven students as vol-
unteers who were assumed to be nonimmune on
the basis of a negative history of rubella and
absence of HAl antibody in serum.
All received 1 mI of a solution containing 104
TCID50 viruses of the attenuated Brown strain
intranasally.' Five days later, five of the students
received (iv) 30-60 mI of gamma globulin di-
luted in 200 mI of saline. Two students (NB and
LT) remained as controls and were isolated.
Both controls developed mild rubella 10-14
days later; one had postauricular lymphade-
nopathy, slight rash and fever, arthralgia, and a
rise in HAl antibodies to 1: 128, while the other
had the same symptoms, except for arthralgia.
The titer of rubella HAl antibodies increased to
1: 1,024 five weeks after inoculation of rubella
virus in the second control subject.
1 Supplied by the National Institute of Allergy and
Infectious Diseases, National Institutes of Health
Bethesda, Md. '
Passive Protection against Rubella
Table 2. Serologic evidence of protection against rubella with intravenous gamma globulin.
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NB (M) 72 0 +
LT (F) 62 0 +
FB (M) 70 60
MF (M) 75 40
TB (F) 63 40
AL(F) 68 30
RS (F) 65 30
Subject
(sex)
Weight
(kg)
Dose of
gamma
globulin
(ml) Symptoms Titer of HAl antibodies
After
Before 24 hr 3 weeks 6 weeks
0 0 1:256 1: 1,024
0 0 1:128 1:128
0 1:6 0 0
0 0 0
0 1:8 0 0
0 1:8 0 0
0 1:8 0 0
Table 2 shows that none of the treated stu-
dents had symptoms of rubella or elevated titers
of antibodies. Three months later one of the stu-
dents was infected by the Brown strain and
showed symptoms of mild disease; he did exhibit
a primary type of antibody response, another
proof that he had been protected earlier by the
gamma globulin. The titer of HAl antibody to
rubella virus in his serum increased from <1:8
before infection to 1: 128 two weeks later and to
1: 1,024 six weeks later.
Discussion
To protect a pregnant woman against rubella,
we need to know when she was infected. Rubella
virus may be cultured from pharyngeal secretions
as early as one week before the onset of rash [5].
However, it is only two to three days before the
onset of rash that the titer of excreted virus is
really high [16]. A second factor to be consid-
ered is the number of days that elapse between
infection and viremia. Viremia can be detected
in the infected person as early as six days after
infection [5, 17]. Therefore, if we want to pro-
tect the fetus, we probably have only five days
between infection and the iv administration of
gamma globulin. The favorable results that we
obtained support the theory that it should be pos-
sible to protect subjects if viremia is prevented.
In practical terms, if a pregnant woman is
exposed to rubella, the first step is to determine
whether or not she is immune [3, 17, 18] by
testing her serum for antibodies. It is generally
accepted that titer of HAl antibodies of 1:8 is
enough for protection.
If she is not immune, 30-40 ml of suitably
treated, standard gamma globulin should be in-
jected as soon as possible. The titer of HAl anti-
bodies to rubella virus 10-25 and 42 days later
will show whether the subject has been protected
from infection.
References
1. Gregg, N. M. Congenital cataract following Ger-
man measles in the mother. Trans. Ophthalmol.
Soc. Aust. 3:35-46, 1942.
2. Angela, G. C., Martinesco, G., Di Nola, F., Zunin,
C., Vacca, C. La Rosolia. Minerva Med. 58:
4759-4826, 1967.
3. Martin, du Pan, R. Quels risques court nne femme
enceinte losque son enfant contacte une rubeole?
Medecine et Hygiene 27:620-623, 1969.
4. Aycock, W. L., Ingalls, T. H. Maternal diseases as
a principle in the epidemiology of congenital
anomalies. Am. J. Med. Sci. 212:366-379, 1946.
5. Green, R. H., Balsama, M. R., Gilles, J. P., Krug-
man, S., Mitrick, G. S. Studies of the natural
history and prevention of rubella. Am. J. Dis.
Child. 110:348-365, 1965.
6. Brody, J. A., Sever, J. L., Schiff, G. M. Prevention
of rubella by gamma globulin during an epi-
demic in Barrow, Alaska in 1964. N. Engl. J.
Med. 272:127-129, 1965.
7. Schiff, G. M. The efficacy of titered lots of im-
mune globulin in preventing rubella. Interna-
tional symposium on rubella vaccines. London
1968. Symposium series on immunobiological
standardization, vol. 2, p. 83-94, 1969.
8. Martin du Pan, R., Scheidegger, J. J., Wenger, P.,
Koechli, B., Roux, J. J. Das Verhalten des intra-
muscular, intravenos und per os verabreichten
gamma globulin. Blut 5: 104-114, 1959.
9. Martin du Pan, R., Wenger, P., Koechli, B., Schei-
degger, J. J., Roux, J. Etude du passage de la
344
gamma globuline marquee a travers Ie placenta
humain. Clin. Chim. Acta 4:110-115, 1959.
10. Martin du Pan, R. Protection of pregnant woman
against rubella. Lancet 2:546, 1969.
11. Wiener, A. S., Gordon, E. B. Studies on human
serum gamma globulin: I. Half-life and rate of
protection. J. Lab. Clin. Med. 49:258-262, 1957.
12. Cockburn, W. C., Harrington, J. A., Zeitlin, R. A.,
Morris D., Camps, F. E. Homologous serum
hepatitis and measles prophylaxis. Br. Med. J.
2:6-8, 1951.
13. Barandun, S. Die gamma-globulin therapie. Bibl.
haematol. 17(Suppl.):7-134, 1964.
14. Barandun, S., Riva, G., Spengler, G. Immunologic
deficiency diagnosis forms and current treatment.
du Pan, Koechli, and Douath
Birth defect: Origin. Series National Foundation
p. 40-46, 1970.
15. Kistler, P., Zahler, P. Probleme bei der Herstellung
intravenos verabreichbarer humaner Gamma
Globulin Losungen, Pathol. Microbiol. 27: 564-
571, 1964.
16. Cooper, L. Z., Krugman, S. Clinical manifestations
of postnatal and congenital rubella. Arch. Oph-
thalmol. 77:434-439, 1967.
17. Schiff, G. M., Sever, J. L. Rubella: recent labora-
tory and clinical advances. Progr, Med. Virol.
8:30-61, 1966.
18. Krugman, S., Ward, R. Demonstration of neutraliz-
ing antibody in gamma globulin and reevaluation
of the rubella problem. N. Engl. J. Med. 259:
16-19, 1958.
